Ru-Xin Foong1,2,3, Mattia Giovannini2,4, George du Toit1,2,3. 1. Children's Allergy Service, Evelina London Children's Hospital, Guy's and St. Thomas' NHS Foundation Trust. 2. Pediatric Allergy Group, Department of Women and Children's Health, School of Life Course Sciences. 3. Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom. 4. Allergy Unit, Department of Pediatrics, Anna Meyer Children's Hospital, University of Florence, Florence, Italy.
Abstract
PURPOSE OF REVIEW: The following article provides an overview of food-dependent exercise-induced anaphylaxis (FD-EIAn). The review focuses on the epidemiology, pathophysiology, and clinical findings of FD-EIAn and details current practice in terms of the investigation, management, and treatment options available. RECENT FINDINGS: The management of FD-EIAn has not changed significantly over the last few years and still requires careful investigation by an experienced clinician to ensure that the correct diagnosis is made and appropriate treatment is given. Although new therapies such as synthetic prostaglandin E1 analogs and IgE monoclonal antibodies have been trialed as treatment options for FD-EIAn, the mainstay of treatment remains the graded reintroduction to exercise in a supervised setting. SUMMARY: FD-EIAn is a rare but serious condition that can have a significant impact on patients' lives. This review aims to discuss new relevant research into this field to help guide clinicians in managing this condition.
PURPOSE OF REVIEW: The following article provides an overview of food-dependent exercise-induced anaphylaxis (FD-EIAn). The review focuses on the epidemiology, pathophysiology, and clinical findings of FD-EIAn and details current practice in terms of the investigation, management, and treatment options available. RECENT FINDINGS: The management of FD-EIAn has not changed significantly over the last few years and still requires careful investigation by an experienced clinician to ensure that the correct diagnosis is made and appropriate treatment is given. Although new therapies such as synthetic prostaglandin E1 analogs and IgE monoclonal antibodies have been trialed as treatment options for FD-EIAn, the mainstay of treatment remains the graded reintroduction to exercise in a supervised setting. SUMMARY:FD-EIAn is a rare but serious condition that can have a significant impact on patients' lives. This review aims to discuss new relevant research into this field to help guide clinicians in managing this condition.